Paradigm Biopharmaceuticals Limited
PBIGF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.1M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $4.10 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.16 |
| Beta | -0.02 |
| Outstanding Shares | 344,426,096 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -1.61 |
|---|---|
| PEG | -1.02 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
February 24, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Paradigm Biopharmaceuticals Limited
8 employees
CEO: Paul John Rennie
Melbourne, Australia-based Paradigm Biopharmaceuticals Limited operates as a drug repurposing company, focusing on the discovery and development of therapeutic products for human application. The company's core offering is an injectable ...